Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Phio Pharmaceuticals Corp. on January 13, 2025. The report discloses "Other Events" (Item 8.01) regarding the announcement of clinical study results for the Company's investigational product, PH-762.
Key Financial Metrics
This filing is a current report focused on clinical developments and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The Company reported promising results from the second cohort of its ongoing clinical study of PH-762. The data covers 4 patients who completed treatment:
- 2 patients with cutaneous squamous cell carcinoma achieved a complete response (100% tumor clearance).
- 1 patient with cutaneous squamous cell carcinoma achieved a partial response (90% tumor clearance).
- 1 patient experienced stable disease with no progression.
Guidance, Outlook, and Risks
The filing incorporates a press release (Exhibit 99.1) detailing these results. No specific financial guidance, forward-looking revenue projections, or new risk factors were disclosed in the text of this 8-K beyond the standard nature of ongoing clinical trials.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed methodology and patient demographics.
- Review the Company's most recent 10-K or 10-Q filings for current financial position, cash runway, and liquidity status, as this 8-K contains no financial data.
- Monitor subsequent filings for updates on the third cohort or regulatory interactions regarding PH-762.